The February 2024 ESHRE Journal Club discussion focused on a study by Mostinckx et al. (2024), reporting their experience with IVM in expected hyper-responders, compared with traditional OS for ICSI; the discussion expanded to possible benefits and limits of IVM, obstacles to overcome for its application in clinical practice and future perspectives. AMH, anti-Müllerian hormone; COC, cumulus–oocyte complex; GV, germinal vesicle; OHSS, ovarian hyperstimulation syndrome; OS, ovarian stimulation; IVM, in vitro maturation; CAPA-IVM, capacitation IVM; MII, meiosis II; OSC-IVM, ovarian support cells-IVM.
No takes yet. Share an insight, caveat, or question.
Makieva et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: